101 related articles for article (PubMed ID: 16922727)
1. E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer.
Lin J; Dinney CP; Grossman HB; Jhamb M; Zhu Y; Spitz MR; Wu X
Clin Genet; 2006 Sep; 70(3):240-5. PubMed ID: 16922727
[TBL] [Abstract][Full Text] [Related]
2. MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation.
Wu L; Xu X; Shen J; Xie H; Yu S; Liang T; Wang W; Shen Y; Zhang M; Zheng S
J Surg Oncol; 2007 Jul; 96(1):62-8. PubMed ID: 17443726
[TBL] [Abstract][Full Text] [Related]
3. No association exists between E-cadherin gene polymorphism and tumor recurrence in patients with hepatocellular carcinoma after transplantation.
Li XD; Wu LM; Xie HY; Xu X; Zhou L; Liang TB; Wang WL; Shen Y; Zhang M; Zheng SS
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):254-8. PubMed ID: 17548247
[TBL] [Abstract][Full Text] [Related]
4. DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder.
Ma X; Xu H; Zheng T; Li HZ; Shi TP; Wang BJ; Ju ZH; Wang C; Zhang GX; Zhang X
BJU Int; 2008 Aug; 102(5):633-6. PubMed ID: 18384629
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese.
Li Y; Liang J; Kang S; Dong Z; Wang N; Xing H; Zhou R; Li X; Zhao X
Gynecol Oncol; 2008 Feb; 108(2):409-14. PubMed ID: 18035404
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer.
Kiemeney LA; van Houwelingen KP; Bogaerts M; Witjes JA; Swinkels DW; den Heijer M; Franke B; Schalken JA; Verhaegh GW
Eur J Cancer; 2006 Dec; 42(18):3219-27. PubMed ID: 16934975
[TBL] [Abstract][Full Text] [Related]
7. A single nucleotide polymorphism in the E-cadherin gene promoter -160 C/A is associated with risk of nasopharyngeal cancer.
Ben Nasr H; Hamrita B; Batbout M; Gabbouj S; Bouaouina N; Chouchane L; Chahed K
Clin Chim Acta; 2010 Sep; 411(17-18):1253-7. PubMed ID: 20462505
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.
Leibovici D; Grossman HB; Dinney CP; Millikan RE; Lerner S; Wang Y; Gu J; Dong Q; Wu X
J Clin Oncol; 2005 Aug; 23(24):5746-56. PubMed ID: 16110031
[TBL] [Abstract][Full Text] [Related]
9. CDH1 C-160A promoter polymorphism and gastric cancer risk.
Corso G; Berardi A; Marrelli D; Pedrazzani C; Garosi L; Pinto E; Roviello F
Eur J Cancer Prev; 2009 Feb; 18(1):46-9. PubMed ID: 19077564
[TBL] [Abstract][Full Text] [Related]
10. Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population.
Medina-Franco H; Ramos-De la Medina A; Vizcaino G; Medina-Franco JL
Ann Surg Oncol; 2007 Aug; 14(8):2246-9. PubMed ID: 17549573
[TBL] [Abstract][Full Text] [Related]
11. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer.
Ahirwar D; Kesarwani P; Manchanda PK; Mandhani A; Mittal RD
Cancer Genet Cytogenet; 2008 Jul; 184(1):1-8. PubMed ID: 18558283
[TBL] [Abstract][Full Text] [Related]
12. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
Tasci AI; Tugcu V; Ozbek E; Ozbay B; Simsek A; Koksal V
BJU Int; 2008 Feb; 101(4):503-7. PubMed ID: 17986285
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
[TBL] [Abstract][Full Text] [Related]
14. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population.
Gangwar R; Mandhani A; Mittal RD
Ann Surg Oncol; 2009 Jul; 16(7):2028-34. PubMed ID: 19412632
[TBL] [Abstract][Full Text] [Related]
15. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
16. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
17. [Association of three single nucleotide polymorphisms of the E-cadherin gene with susceptibility to epithelial ovarian carcinoma].
Liang J; Li Y; Wang N
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):183-6. PubMed ID: 18393242
[TBL] [Abstract][Full Text] [Related]
18. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
[TBL] [Abstract][Full Text] [Related]
19. Significance of an E-cadherin gene promoter polymorphism for risk and disease severity of prostate cancer in a Japanese population.
Goto T; Nakano M; Ito S; Ehara H; Yamamoto N; Deguchi T
Urology; 2007 Jul; 70(1):127-30. PubMed ID: 17656222
[TBL] [Abstract][Full Text] [Related]
20. The E-cadherin -347G->GA promoter polymorphism and its effect on transcriptional regulation.
Shin Y; Kim IJ; Kang HC; Park JH; Park HR; Park HW; Park MA; Lee JS; Yoon KA; Ku JL; Park JG
Carcinogenesis; 2004 Jun; 25(6):895-9. PubMed ID: 14729585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
